Abbisko Cayman (HKG:2256) stated that Merck has exercised its global commercialization option for pimicotinib (ABSK021) under a 2023 licensing agreement, granting Merck exclusive worldwide rights to the CSF-1R inhibitor, according to a filing with the Hong Kong bourse on Tuesday.
Abbisko received an $85 million exercise fee for its option. This adds to the $70 million upfront payment received earlier, with potential total payments reaching $605.5 million.
The decision follows positive Phase III results for pimicotinib in treating tenosynovial giant cell tumor (TGCT). Abbisko continues advancing its precision oncology pipeline while maintaining collaboration with Merck.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。